"Quinazolines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
Descriptor ID |
D011799
|
MeSH Number(s) |
D03.633.100.786
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Quinazolines".
Below are MeSH descriptors whose meaning is more specific than "Quinazolines".
This graph shows the total number of publications written about "Quinazolines" by people in this website by year, and whether "Quinazolines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Below are the most recent publications written about "Quinazolines" by people in Profiles.
-
Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database. Leuk Res. 2022 08; 119:106903.
-
A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Sep; 138(3):507-12.
-
Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer. Anticancer Res. 2012 May; 32(5):1705-10.
-
PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy. Br J Cancer. 2011 Dec 06; 105(12):1920-6.
-
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2008 Nov 20; 26(33):5407-15.
-
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. Clin Cancer Res. 2008 Apr 01; 14(7):2088-94.
-
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol. 2004 Aug 15; 22(16):3238-47.
-
Epidermal growth factor receptor-targeted therapy and symptom improvement in non-small cell lung cancer. Am J Health Syst Pharm. 2003 Dec 15; 60(24 Suppl 9):S16-21.